MSDC-0602, an insulin sensitizer is selective for a molecular target, mTOT, which connects mitochondrial metabolism to important cell functions.
Recent Phase 2a study in patients suffering with type 2 diabetes demonstrated that MSDC-0602 significantly controlled the glucose level and increased insulin sensitivity.
Preclinical studies in a rodent model of FLD funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) also showed that MSDC-0602 improved insulin sensitivity and the ability of the liver to oxidize and clear fat.
MSDC CEO Stephen Benoit said the mTOT biochemical pathway will enable their researchers to select compounds that treat the root cause of various health issues affecting Americans today.